Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/03/2026 | Q4 | $16.2B | -- | -- | $2.05 | -- |
| 10/30/2025 | Q3 | $17B | $17.2B | $2.32 | $2.35 | -$0.03 |
| 07/29/2025 | Q2 | $15.9B | $15.8B | $1.76 | $2.03 | -$0.27 |
| 04/24/2025 | Q1 | $15.3B | $15.6B | $2.01 | $2.14 | -$0.13 |
| 02/04/2025 | Q4 | $15.5B | $15.3B | $1.48 | $1.67 | -$0.19 |
| 10/31/2024 | Q3 | $16.5B | $16.7B | $1.24 | $1.57 | -$0.33 |
| 07/30/2024 | Q2 | $15.8B | $16.2B | $2.14 | $2.14 | -$0.00 |
| 04/25/2024 | Q1 | $15.2B | $15.8B | $1.87 | $1.92 | -$0.05 |
| 02/01/2024 | Q4 | $14.5B | $14.2B | -$0.48 | -$0.11 | -$0.37 |
| 10/26/2023 | Q3 | $15.3B | $16B | $1.86 | $1.95 | -$0.08 |
| 08/01/2023 | Q2 | -- | $15.1B | -$2.35 | -- | -- |
| 04/27/2023 | Q1 | -- | $14.6B | $1.11 | -- | -- |
| 02/02/2023 | Q4 | -- | $12.5B | $1.18 | -- | -- |
| 10/27/2022 | Q3 | -- | $15.2B | $1.28 | -- | -- |
| 07/28/2022 | Q2 | -- | $14.8B | $1.55 | -- | -- |
| 04/28/2022 | Q1 | -- | $16B | $1.70 | -- | -- |
| 02/03/2022 | Q4 | -- | $13.9B | $1.48 | -- | -- |
| 10/28/2021 | Q3 | -- | $13.1B | $1.80 | -- | -- |
| 07/29/2021 | Q2 | -- | $11.3B | $0.61 | -- | -- |
| 04/29/2021 | Q1 | -- | $10.5B | $1.25 | -- | -- |
| 02/04/2021 | Q4 | -- | $10.9B | -$0.83 | -- | -- |
| 10/27/2020 | Q3 | -- | $10.9B | $1.16 | -- | -- |
| 07/31/2020 | Q2 | -- | $9.3B | $1.18 | -- | -- |
| 04/28/2020 | Q1 | -- | $12B | $1.26 | -- | -- |
| 02/05/2020 | Q4 | -- | $11.8B | $0.92 | -- | -- |
| 10/29/2019 | Q3 | -- | $12.3B | $0.74 | -- | -- |
| 07/30/2019 | Q2 | -- | $11.7B | $1.03 | -- | -- |
| 04/30/2019 | Q1 | -- | $10.8B | $1.12 | -- | -- |
| 02/01/2019 | Q4 | -- | $11B | $0.69 | -- | -- |
| 10/25/2018 | Q3 | -- | $10.8B | $0.73 | -- | -- |
| 07/27/2018 | Q2 | -- | $10.3B | $0.63 | -- | -- |
| 05/01/2018 | Q1 | -- | $10.1B | $0.27 | -- | -- |
| 02/02/2018 | Q4 | -- | $10.4B | -$0.39 | -- | -- |
| 10/27/2017 | Q3 | -- | $10.3B | -$0.02 | -- | -- |
| 07/28/2017 | Q2 | -- | $9.9B | $0.71 | -- | -- |
| 05/02/2017 | Q1 | -- | $9.3B | $0.56 | -- | -- |
| 02/02/2017 | Q4 | -- | $10.1B | -$0.22 | -- | -- |
| 10/25/2016 | Q3 | -- | $10.5B | $0.78 | -- | -- |
| 07/29/2016 | Q2 | -- | $9.8B | $0.43 | -- | -- |
| 05/05/2016 | Q1 | -- | $9.2B | $0.40 | -- | -- |
| 02/03/2016 | Q4 | -- | $10B | $0.35 | -- | -- |
Merck & Co., Inc. reported $17.2B worth of top line sales in its most recent quarter.
Merck & Co., Inc. announced earnings per share of $2.32 which represents a miss of analyst forecast a $2.35 per share.
Merck & Co., Inc. reported $13B that represents $5.20 per share over the last quarter.
Merck & Co., Inc.'s earnings are forecast to grow from $6.74 per share to $7.61 per share next year representing an increase of 33.22%.
Merck & Co., Inc.'s next earnings date is February 3, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.